Interleukin-23 Secreted by Activated Macrophages Drives gamma delta T Cell Production of Interleukin-17 to Aggravate Secondary Injury After Intracerebral Hemorrhage
Interleukin-23 Secreted by Activated Macrophages Drives gamma delta T Cell Production of Interleukin-17 to Aggravate Secondary Injury After Intracerebral Hemorrhage
复制标题
活化巨噬细胞分泌的白细胞介素23驱动γδT细胞产生白细胞介素17,加重脑出血后的继发性损伤
DOI:
10.1161/jaha.116.004340
复制
发表时间:
2016
影响因子:
5.4
通讯作者:
Yang Qing-Wu
中科院分区:
文献类型:
--
作者:
Zhong Qi;Zhou Kai;Liang Qiao-Li;Lin Sen;Wang Yan-Chun;Xiong Xiao-Yi;Meng Zhao-You;Zhao Ting;Zhu Wen-Yao;Yang Yuan-Rui;Liao Mao-Fan;Gong Qiu-Wen;Liu Liang;Xiong Ao;Hao Junwei;Wang Jian;Yang Qing-Wu
BackgroundNeuroinflammation plays a key role in intracerebral hemorrhage (ICH)–induced secondary brain injury, but the specific roles of peripheral inflammatory cells such as macrophages and lymphocytes remain unknown. The purpose of this study was to explore the roles of macrophages, T lymphocytes, and the cytokines they secrete as potential targets for treating secondary brain injury after ICH.Methods and ResultsOur results showed that peripheral macrophages and T lymphocytes successively infiltrated the brain, with macrophage counts peaking 1 day after ICH and T‐lymphocyte counts peaking after 4 days. These peaks in cellular infiltration corresponded to increases in interleukin (IL)‐23 and IL‐17 expression, respectively. We found that hemoglobin from the hematoma activated IL‐23 secretion by infiltrating macrophages by inducing the formation of toll‐like receptor (TLR) 2/4 heterodimer. This increased IL‐23 expression stimulated γδT‐cell production of IL‐17, which increased brain edema and neurologic deficits in the model mice as a proinflammatory factor. Finally, we found that sparstolonin B (SsnB) could ameliorate brain edema and neurologic deficits in ICH model mice via inhibition of TLR2/TLR4 heterodimer formation, and notably, SsnB interacted with myeloid differentiation factor 88 Arg196.ConclusionsTogether, our results reveal the importance of the IL‐23/IL‐17 inflammatory axis in secondary brain injury after ICH and thus provide a new therapeutic target for ICH treatment.